ASX Announcement: AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics
Highlights: * AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets * Combining Carina's advanced CAR-T platform technologies with AdAlta's i–body targeting capability aims to create un...
Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd
* Experienced Pharmaceutical Executive * Decades of global business development, strategy and biologic drug development experience * Expertise to drive the next phase of AdAlta's growth MELBOURNE, Australia, Oct. 9, 2019 /PRNewswire/ -- The Board of AdAlta Limited (ASX:1AD), is pleased to a...
AdAlta secures licensing deal for the i-body platform with global medical technology and diagnostics firm, GE Healthcare
Highlights * AdAlta secures commercial agreement for its i-body platform with global medical technology and diagnostics firm, GE Healthcare. * Under the licensing deal, the two companies will develop i-bodies for diagnostic imaging. * AdAlta will screen its novel i-body library on a number ...
